[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Oxford Biodynamics Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":52},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100564959",false,"NCT06635954","A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.","PROWES","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Stage III or IV cancer\n3. Selected by their healthcare provider to receive the Episwitch CiRT® test according to the current evidence-based schedule (per protocol) as part of their standard of practice.\n4. ECOG performance status ≤ 2\n5. Clinically eligible for ICI therapy\n6. Able to read, understand and provide written informed consent.\n7. Willing and able to comply with the study requirements\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding\n2. History of bone marrow or organ transplant\n3. Contra indication for receiving Immune Check Point inhibitor.","ALL","18 Years",{"count":18,"type":19},2000,"ESTIMATED","OBSERVATIONAL","The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.",[23,24,25,26,27],"Cancer","Immunotherapy","PD-1","PD-L1","Immune Checkpoint Therapy",[29,30,31,32,33,34,35,36,37,38,25,26],"immunotherapy","immune checkpoint inhibitor","ICI therapy","ICI","Immune Checkpoint Inhibitor therapy","Episwitch","Episwitch CiRT","Immune Related Adverse Event","IRAE","cancer","RECRUITING","2025-03-12",{"date":42,"type":43},"2025-03-17","ACTUAL",{"date":45,"type":43},"2024-05-14",{"date":47,"type":19},"2027-05-14",{"name":49,"class":50},"Oxford Biodynamics Inc.","INDUSTRY",3,""]